The ARC Foundation supports the PRISM-Breast project

15 octobre 2020

The « Prism-Breast » project aims to understand the determinants of tumor response to anti-PD1 and beyond in patients who develop early stage triple negative breast cancer.

Triple negative breast cancers represent 15% of breast cancers and most often have a poor prognosis. This subtype is considered immunogenic, anti-PD(L)1 antibodies having shown their effectiveness in several recent studies.

The Prism-breast project will test the hypothesis that immunotherapy (Durvalumab) initiated early in women with localized (non-metastatic) triple-negative breast cancer could cure some of them. The POP-Durva study, developed to validate this hypothesis, aims that at least 20% of these women will be cured. In parallel, from biological samples collected from diagnosis and throughout the trial, the PRISM-sein project will seek to identify the biological characteristics associated with sensitivity or resistance to immunotherapy.

 Prism est un partenariat unique entre


Centre National de Médecine de Précision en Oncologie

Nous contacter

Prism  IHU-B

Bâtiment de médecine moléculaire

32 Rue Camille Desmoulins

94800 Villejuif

Tél. +33(0)1 42 11 00 00

info -at-



Rejoindre nos équipes

Appels à projets


Les cookies

Mentions légales

Réseaux sociaux